Respiratory Medicine Case Reports · 2017 · 16 citations · 18 references
MedicineImmunologyPathologyEarly DetectionInflammationPulmonologyFibrosisInterstitial Lung DiseasePulmonary InflammationRespiratory DiseaseSystemic SclerosisConnective Tissue Disease - Associated Interstitial Lung DiseaseConnective Tissue Disease-associated Interstitial Lung DiseaseEarly ScreeningFibrosis In Systemic SclerosisFibrotic Interstitial Lung DiseaseInterstitital Lung DiseaseScleroderma TreatmentTreatment Strategies
Scleroderma-related interstitial lung disease (SSc-ILD) is a pulmonary fibrosing disorder characterized by systemic inflammation and progressive scarring of the lungs that leads to respiratory failure. Although certain immunosuppressive therapies may slow disease progression, current treatment strategies are not curative; consequently, SSc-ILD continues to be a major cause of morbidity and mortality. We present four cases of SSc-ILD that emphasize the importance of early screening and detection, close follow-up, and aggressive management. We also highlight the need for well-conducted clinical trials designed to identify new and effective treatments.
18
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Luca Richeldi, Roland M. du Bois, Ganesh Raghu et al. · New England Journal of Medicine · 2014 · 4.6K citations · Full text
Cyclophosphamide versus Placebo in Scleroderma Lung Disease
Donald P. Tashkin, Robert M. Elashoff, Philip J. Clements et al. · New England Journal of Medicine · 2006 · 1.7K citations · Full text
Donald P. Tashkin, Michael D. Roth, Philip J. Clements et al. · The Lancet Respiratory Medicine · 2016 · 1.1K citations
Demosthenes Bouros, Athol U. Wells, Andrew G. Nicholson et al. · American Journal of Respiratory and Critical Care Medicine · 2002 · 820 citations